<p>Drugs for focused treatments are fundamentally monoclonal antibodies, microRNA, meddling RNA atoms, and small molecule inhibitors. The utilization by the modern specialists creates a multidimensional advancement in the field pharmacokinetics of these medications. Individual pharmacokinetics changeability is regularly enormous, and capriciousness is seen in the reaction to the pharmacogenetic data of the patient, quiet qualities. An overall study of all the factors, along with the somatic genome, helps determine anticancer drug response more accurately and safely. Observing individual pharmacogenomic profiles provides oncologists with new resources to formulate the treatment for their patients by maximizing efficiency and minimizing toxicity. This paper recapitulates the pre-existing attributes associated with the pharmacogenomics of anticancer drugs, the classification of drugs, and a comparative analysis between targeted therapy and other methods and further discusses the greater opportunities for the advancement of these therapies and drugs for improving a cancer-free world. Until this point, the therapeutic observation of monoclonal antibodies and small molecule inhibitors has not yet been upheld by weighty logical proof. In light of this, the clinician ought to assess favorable circumstances and constraints, with respect to viability and relevance, of the most appropriate pharmacological way to deal with playing out a customized treatment.</p>